Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gelmon, K. A.
Right arrow Articles by Seymour, L. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gelmon, K. A.
Right arrow Articles by Seymour, L. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:1115-1122, 2004
© 2004 European Society for Medical Oncology

A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131

Background: AMD473 (previously ZD0473) is a new-generation platinum compound with activity against a wide range of human tumour cell lines and xenografts, including carboplatin- and cisplatin-resistant lines. To assess its potential combined with a taxane, a phase I study of AMD473 and docetaxel in advanced cancer was initiated by the National Cancer Institute of Canada-Clinical Trials Group.

Patients and methods: Patients with advanced cancer, measurable disease, performance status Eastern Cooperative Oncology Group 0–2, no major organ dysfunction, and one or no previous taxane regimen received escalating doses of AMD473 and docetaxel every 3 weeks, with a starting dose of AMD473 80 mg/m2 and docetaxel 60 mg/m2.

Results: Thirty-three patients enrolled on four dose levels were evaluable for toxicity and 25 patients were evaluable for response. The maximum tolerated dose was dose level 4 (AMD473 120 mg/m2 and docetaxel 75 mg/m2), with grade 4 neutropenia in both minimally and heavily pretreated patients causing dose-limiting toxicity. As well at dose level 4, one patient had grade 3 vomiting despite premedication. Dose level three was expanded for both groups of patients and was defined as the recommended phase II dose at AMD473 100 mg/m2 and docetaxel 75 mg/m2. Non-hematologic toxicities included fatigue, diarrhoea and other mild toxicities. There was one partial response in a patient with prostate cancer and stable disease in 15 patients. No apparent pharmacokinetic interaction was noted.

Conclusion: AMD473 and docetaxel can be combined with a recommended phase II dose level of 100 mg/m2 and 75 mg/m2, respectively, given intravenously every 3 weeks. The combination has activity and should be explored in responsive tumour types.

K. A. Gelmon1,2,*, D. Stewart2,3, K. N. Chi1,2, S. Chia1,4, C. Cripps2,3, S. Huan2,3, S. Janke1,2, D. Ayers1,2, D. Fry2,3, J. A. Shabbits1, W. Walsh2, L. McIntosh2 and L. K. Seymour2

1 British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC; 2 NCIC Clinical Trials Group, Kingston, ON; 3 Ottawa Regional Cancer Centre, Ottawa, ON, Canada

*Correspondence to: Dr K. A. Gelmon, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC, Canada V5Z 4E6. Tel: +1-604-877-6000; Fax: +1-604-877-0585; Email: kgelmon{at}bccancer.bc.ca

Key words: AMD473, docetaxel, phase I studies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.